Related Experiment Video
Updated: Jun 2, 2025
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
172
Intralesional Bleomycin for Orbital Venolymphatic Malformation.
Kit May Chow1, Kala Sumugam1, Amali Ahmad2
1Department of Ophthalmology, Hospital Kuala Lumpur, Kuala Lumpur, MYS.
Cureus
|January 13, 2025
Summary
Intralesional bleomycin injections effectively treat orbital venolymphatic malformations (OVLM), reducing lesion size and symptoms. This safe treatment option is beneficial for recurrent cases or when surgery is not feasible.
Area of Science:
- Ophthalmology
- Vascular Surgery
Background:
- Orbital venolymphatic malformations (OVLM) are complex vascular anomalies.
- Treatment options for OVLM can be limited, especially for recurrent or extensive cases.
Observation:
- A case series evaluated three patients with OVLM, including two with recurrent disease after failed sclerotherapy.
- Patients received multiple doses of intralesional bleomycin injections.
Findings:
- Intralesional bleomycin injections led to significant reductions in OVLM size, decreased proptosis, and pain relief.
- The treatment was well-tolerated with no reported ophthalmic or systemic side effects.
- Complete symptom resolution was not achieved in all cases.
Implications:
- Bleomycin is an effective and safe sclerosing agent for treating OVLM.
- Intralesional bleomycin injections offer a valuable alternative for managing challenging OVLM cases, particularly when other therapies fail or surgery is not an option.
